Get started
Author

Martin Highley

Observed names: M Highley, M S Highley, M. Highley, M. S. Highley, M.S Highley, M.S. HIGHLEY, M.S. Highley, MS Highley, Martin S Highley, Martin S. Highley
Institution: Derriford Hospital
Observed institutions: Guy's Hospital, University of Leeds, St George's Hospital, University of Dundee, Royal Devon & Exeter NHS Foundation Trust, Western General Hospital, Universitair Ziekenhuis Leuven, Beatson West of Scotland Cancer Centre, Aberdeen Royal Infirmary, Western Infirmary, Royal Devon and Exeter Hospital, Newcastle upon Tyne Hospitals NHS Foundation Trust, Ninewells Hospital, Derriford Hospital, Antwerp University Hospital, Centre Léon Bérard, Royal Marsden Hospital, Newcastle upon Tyne Hospital, Addenbrooke's Hospital, Plymouth Hospital, University Hospitals Plymouth NHS Trust, Daniel den Hoed Kliniek, University of Glasgow, Newcastle University, University of Plymouth, KU Leuven
ORCID: 0000-0002-3400-868X
Observed ORCID: 0000-0002-3400-868X
OpenAlex ID: A5079189753
Vascular Endothelial Growth Factor and Angiogenesis
2004 · Ann Hoeben, Bart Landuyt, et al. · Pharmacological Reviews · 1,829
Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
2009 · J W Valle, H Wasan, et al. · British Journal of Cancer · 271
PDF
Phase III Randomized Trial of Doxorubicin and Docetaxel Versus Doxorubicin and Cyclophosphamide As Primary Medical Therapy in Women With Breast Cancer: An Anglo-Celtic Cooperative Oncology Group Study
2005 · T.R. Jeffry Evans, Ann Yellowlees, et al. · Journal of Clinical Oncology · 175
Estimation of glomerular filtration rate in cancer patients
2001 · J G Wright, A V Boddy, et al. · British Journal of Cancer · 170
PDF
Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
2016 · Yvette Drew, Jonathan Ledermann, et al. · British Journal of Cancer · 162
PDF
Pharmacology of Anticancer Drugs in the Elderly Population
2003 · Hans Wildiers, Martin S Highley, et al. · Clinical Pharmacokinetics · 126
Oxidative DNA Damage: Biological Significance and Methods of Analysis
2002 · Gunther Guetens, Gert De Boeck, et al. · Critical Reviews in Clinical Laboratory Sciences · 125
Treatment of Invasive Thymoma With Single-Agent Ifosfamide
1999 · M. S. Highley, C. R. Underhill, et al. · Journal of Clinical Oncology · 97
Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2/3 trial
2023 · Janet E Brown, Kara-Louise Royle, et al. · The Lancet Oncology · 85
PDF
The Nitrogen Mustards
2022 · Martin S. Highley, Bart Landuyt, et al. · Pharmacological Reviews · 72
PDF
Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial
2018 · P.G. Corrie, P.G. Corrie, et al. · Annals of Oncology · 68
PDF
Imaging Modality and Frequency in Surveillance of Stage I Seminoma Testicular Cancer: Results From a Randomized, Phase III, Noninferiority Trial (TRISST)
2022 · Johnathan K. Joffe, Fay H. Cafferty, et al. · Journal of Clinical Oncology · 61
Nanotechnology in bio/clinical analysis
2000 · G Guetens, K Van Cauwenberghe, et al. · Journal of Chromatography B Biomedical Sciences and Applications · 61
Erythrocytes and the Transport of Drugs and Endogenous Compounds
1996 · Martin S. Highley, Ernst A. De Bruijn · Pharmaceutical Research · 55
Quantification of the anticancer agent STI-571 in erythrocytes and plasma by measurement of sediment technology and liquid chromatography–tandem mass spectrometry
2003 · Gunther Guetens, Gert De Boeck, et al. · Journal of Chromatography A · 45
Combination chemotherapy with epirubicin, cisplatin and 5-fluorouracil for the palliation of advanced gastric and oesophageal adenocarcinoma
1994 · M S Highley, F X Parnis, et al. · British journal of surgery · 38
Phase II trial of the poly(ADP-ribose) polymerase (PARP) inhibitor AG-014699 in BRCA 1 and 2–mutated, advanced ovarian and/or locally advanced or metastatic breast cancer.
2011 · Y. Drew, J. A. Ledermann, et al. · Journal of Clinical Oncology · 37
Seizures and cortical dysfunction following high‐dose cisplatin administration in children
1992 · Martin Highley, Simon T. Meller, et al. · Medical and Pediatric Oncology · 36
Activated oxazaphosphorines are transported predominantly by erythrocytes
1997 · M.S. Highley, D. Schrijvers, et al. · Annals of Oncology · 33
PDF
Erratum: Phase 2 multicentre trial investigating intermittent and continuous dosing schedules of the poly(ADP-ribose) polymerase inhibitor rucaparib in germline BRCA mutation carriers with advanced ovarian and breast cancer
2016 · Yvette Drew, Jonathan Ledermann, et al. · British Journal of Cancer · 30
PDF
Hyphenated techniques in anticancer drug monitoring
2002 · G Guetens, G De Boeck, et al. · Journal of Chromatography A · 30
Phase I study of TNFα AutoVaccIne in Patients with metastatic cancer
2005 · A. M. Waterston, L. Gumbrell, et al. · Cancer Immunology Immunotherapy · 29
Intravesical Drug Delivery
1999 · Martin S. Highley, Allan T. van Oosterom, et al. · Clinical Pharmacokinetics · 29
Partitioning of Ifosfamide and Its Metabolites between Red Blood Cells and Plasma
1996 · Guido Momerency, Karel Van Cauwenberghe, et al. · Journal of Pharmaceutical Sciences · 27
Multicenter phase II study of gemcitabine in previously untreated patients with advanced epithelial ovarian cancer
2001 · C R Underhill, F X Parnis, et al. · Anti-Cancer Drugs · 25
Works count: 88
Citation count: 4,250
H-index: 25
I10-index: 55
Year
Topic
Type